State Street
QNCX icon

State Street’s Quince Therapeutics QNCX Stock Holding History

State Street’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,240
Closed -$25.1K – 4252
2026
Q1 		$25.1K Buy
1,240
+87
+8% +$17.5K ﹤0.01% 4201
2025
Q4 		$773K Buy
1,153
+162
+16% +$81.5K ﹤0.01% 3582
2025
Q3 		$323K Buy
991
+366
+59% +$122K ﹤0.01% 3764
2025
Q2 		$206K Hold
625
– – ﹤0.01% 3825
2025
Q1 		$166K Hold
625
– – ﹤0.01% 3869
2024
Q4 		$234K Buy
625
+342
+121% +$103K ﹤0.01% 3815
2024
Q3 		$43.9K Hold
283
– – ﹤0.01% 4120
2024
Q2 		$42.5K Hold
283
– – ﹤0.01% 4168
2024
Q1 		$60K Hold
283
– – ﹤0.01% 4127
2023
Q4 		$59.4K Hold
283
– – ﹤0.01% 4165
2023
Q3 		$63.4K Hold
283
– – ﹤0.01% 4227
2023
Q2 		$85.2K Sell
283
-4
-1% -$1.25K ﹤0.01% 4279
2023
Q1 		$89.6K Hold
287
– – ﹤0.01% 4351
2022
Q4 		$36.6K Hold
287
– – ﹤0.01% 4626
2022
Q3 		$76K Hold
287
– – ﹤0.01% 4554
2022
Q2 		$127K Sell
287
-1,806
-86% -$1.28M ﹤0.01% 4408
2022
Q1 		$2.59M Buy
2,093
+104
+5% +$142K ﹤0.01% 3471
2021
Q4 		$5.02M Sell
1,989
-2,216
-53% -$13.5M ﹤0.01% 3240
2021
Q3 		$77.1M Sell
4,205
-609
-13% -$9.69M ﹤0.01% 1476
2021
Q2 		$51M Sell
4,814
-515
-10% -$4.32M ﹤0.01% 1831
2021
Q1 		$38.4M Buy
5,329
+1,206
+29% +$8.68M ﹤0.01% 1933
2020
Q4 		$22.9M Buy
4,123
+2,691
+188% +$23.8M ﹤0.01% 2166
2020
Q3 		$14.3M Buy
1,432
+6
+0.4% +$54.6K ﹤0.01% 2232
2020
Q2 		$13.2M Buy
1,426
+456
+47% +$4.18M ﹤0.01% 2265
2020
Q1 		$8.85M Buy
970
+90
+10% +$888K ﹤0.01% 2351
2019
Q4 		$9.88M Buy
880
+626
+246% +$3.78M ﹤0.01% 2529
2019
Q3 		$1.27M Buy
254
+62
+32% +$381K ﹤0.01% 3351
2019
Q2 		$976K Buy
+192
New +$1.15M ﹤0.01% 3424

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's QNCX Position: Q2 2026 in Review

State Street sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 1,240 shares — an estimated $25.1K sold.

State Street first reported a position in QNCX in Q2 2019 and held it in 28 quarters. The position peaked at $77.1M in Q3 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • State Street reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • State Street sold 1,240 Quince Therapeutics shares in Q2 2026, an estimated $25.1K.
  • State Street first reported a position in Quince Therapeutics in Q2 2019 and held it in 28 quarters.
  • State Street's Quince Therapeutics position peaked at $77.1M in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.